HSK16149 20mg BID + HSK16149 40mg BID + Placebo BID
Phase 3Completed 0 watching 0 views this week📈 Rising
74
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 24
Phase 35
ApprovedIndication / Disease
Postherpetic Neuralgia
Conditions
Postherpetic Neuralgia
Trial Timeline
Nov 1, 2021 → Jan 5, 2023
NCT ID
NCT05140863About HSK16149 20mg BID + HSK16149 40mg BID + Placebo BID
HSK16149 20mg BID + HSK16149 40mg BID + Placebo BID is a phase 3 stage product being developed by Haisco Pharmaceutical Group for Postherpetic Neuralgia. The current trial status is completed. This product is registered under clinical trial identifier NCT05140863. Target conditions include Postherpetic Neuralgia.
Hype Score Breakdown
Clinical
27
Activity
18
Company
7
Novelty
9
Community
10
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT05140863 | Phase 3 | Completed |
Competing Products
20 competing products in Postherpetic Neuralgia
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| QUTENZA | Astellas Pharma | Approved | 85 |
| KHK6188 + Placebo | Kyowa Kirin | Phase 2 | 52 |
| ONO-1110 + Placebo | Ono Pharmaceutical | Phase 2 | 52 |
| Placebo + Pregabalin SR tablet 165mg/day + Pregabalin SR tablet 330mg/day + Pregabalin SR tablet 660mg/day | Jiangsu Hengrui Medicine | Phase 3 | 77 |
| MK-8291 + Placebo | Merck | Phase 1 | 33 |
| Etoricoxib + Placebo | Merck | Approved | 85 |
| ADL5747 + Placebo + Pregabalin | Merck | Phase 2 | 52 |
| MK0759 | Merck | Phase 2 | 52 |
| MK0686 | Merck | Phase 2 | 52 |
| Comparator: pregabalin + Comparator: Placebo (unspecified) | Merck | Phase 1 | 33 |
| Lyrica (pregabalin) + Placebo | Pfizer | Approved | 84 |
| RN624 + RN624 + Placebo | Pfizer | Phase 2 | 51 |
| T-62 | Pfizer | Phase 2 | 51 |
| pregabalin + pregabalin/PF-00489791 + Placebo | Pfizer | Phase 2 | 51 |
| PH-797804 + Placebo | Pfizer | Phase 2 | 51 |
| Placebo + Pregabalin + Pregabalin + Pregabalin | Pfizer | Phase 3 | 76 |
| pregabalin | Pfizer | Phase 3 | 76 |
| pregabalin | Pfizer | Approved | 84 |
| T-62 Dose 1 + T-62 Dose 2 | Pfizer | Phase 2 | 51 |
| Levetiracetam | UCB | Phase 2 | 49 |